AIM: To determine the therapeutic effect of lamivu- dine in late pregnancy for the interruption of motherto-child transmission (MTCT) of hepatitis B virus (HBV). METHODS: Studies were identified by searching ava...AIM: To determine the therapeutic effect of lamivu- dine in late pregnancy for the interruption of motherto-child transmission (MTCT) of hepatitis B virus (HBV). METHODS: Studies were identified by searching available databases up to January 2011. Inclusive criteria were HBV-carrier mothers who had been involved in randomized controlled clinical trials (RCTs) with lamivudine treatment in late pregnancy, and newborns or infants whose serum hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) or HBV DNA had been documented. The relative risks (RRs) for inerruption of MTCT as indicated by HBsAg, HBV DNA or HBeAg of newborns or infants were calculated with 95% confidence interval (CI) to estimate the efficacy of lamivudine treatment. RESULTS: Fifteen RCTs including 1693 HBV-carrier mothers were included in this meta-analysis. The overall RR was 0.43 (95% CI, 0.25-0.76; 8 RCTs; Phet- erogeneity= 0.04) and 0.33 (95% CI, 0.23-0.47; 6 RCTs; Pheterogeneity = 0.93) indicated by newborn HBsAg or HBV DNA. The RR was 0.33 (95% CI, 0.21-0.50; 6 RCTs; Pheterogeneity = 0.46) and 0.32 (95% CI, 0.20-0.50; 4 RCTs; Pheterogeneity = 0.33) indicated by serum HBsAg or HBV DNA of infants 6-12 mo after birth. The RR (lamivudine vs hepatitis B immunoglobulin) was 0.27 (95% CI, 0.16-0.46; 5 RCTs; Pheterogeneity = 0.94) and 0.24 (95% CI, 0.07-0.79; 3 RCTs; Pheterogeneity = 0.60) indicated by newborn HBsAg or HBV DNA, respectively. In the mothers with viral load 〈 106 copies/mL after lamivudine treatment, the efficacy (RR, 95% CI) was 0.33, 0.21-0.53 (5 RCTs; Pheterogeneity = 0.82) for the interruption of MTCT, however, this value was not significant if maternal viral load was 〉 106 copies/mL after lamivudine treatment (P = 0.45, 2 RCTs), as indicated by newborn serum HBsAg. The RR (lamivudine initiated from 28 wk of gestation vs control) was 0.34 (95% CI, 0.22-0.52; 7 RCTs; Pheterogeneity = 0.92) and 0.33 (95% CI, 0.22-0.50; 5 RCTs; Pheterogeneity = 0.86) indicated by newborn HBsAg or HBV DNA. The incidence of adverse effects of lamivudine was not higher in the mothers than in controls (P = 0.97). Only one study reported side effects of lamivudine in newborns. CONCLUSION: Lamivudine treatment in HBV carrier- mothers from 28 wk of gestation may interrupt MTCT of HBV efficiently. Lamivudine is safe and more efficient than hepatitis B immunoglobulin in interrupting MTCT. HBV MTCT might be interrupted efficiently if maternal viral load is reduced to 〈 106 copies/mL by lamivudine treatment.展开更多
OBJECTIVES: To explore the distribution of TCM patterns in ketamine users and the inter-rater reli- ability of TCM diagnosis among TCM practitioners. METHODS: Eighty-four subjects recruited from sub- stance abuse cl...OBJECTIVES: To explore the distribution of TCM patterns in ketamine users and the inter-rater reli- ability of TCM diagnosis among TCM practitioners. METHODS: Eighty-four subjects recruited from sub- stance abuse clinics and non-governmental coun- seling services catering for ketamine abusers were examined by one or two TCM practitioners. The dis- tribution and inter-rater reliability of the TCM diag- noses between the two TCM practitioners were de- scribed and measured. RESULTS: Seven TCM patterns were differentiated. The four most common patterns were the Heart Yin deficiency (29.8%), Kidney Yang deficiency (26.2%), Kidney Yin deficiency (19.0%), and Spleen Yang defi-ciency (14.3%). The agreement between the two TCM practitioners was 59%, the kappa for the three most common patterns was 0.472 (P=O.O03). The proportion of men was lower in the Kidney Yin defi- ciency group (18.8%), in comparison to the Heart Yin deficiency (60.0%, P=0.009) and Kidney Yang de- ficiency group (59.1%, P=0.013). CONCLUSION: The differences between the TCM groups in terms of the source of referral and num- ber of drug uses other than ketamine were of bor- derline significance. Further research should focus on validating diagnostic tools and improving in- ter-rater reliability in TCM to enhance the quality of clinical trials of TCM treatments for ketamine abuse.展开更多
基金Supported by National Natural Science Foundation of China,No. 81025015 and No. 30921006
文摘AIM: To determine the therapeutic effect of lamivu- dine in late pregnancy for the interruption of motherto-child transmission (MTCT) of hepatitis B virus (HBV). METHODS: Studies were identified by searching available databases up to January 2011. Inclusive criteria were HBV-carrier mothers who had been involved in randomized controlled clinical trials (RCTs) with lamivudine treatment in late pregnancy, and newborns or infants whose serum hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) or HBV DNA had been documented. The relative risks (RRs) for inerruption of MTCT as indicated by HBsAg, HBV DNA or HBeAg of newborns or infants were calculated with 95% confidence interval (CI) to estimate the efficacy of lamivudine treatment. RESULTS: Fifteen RCTs including 1693 HBV-carrier mothers were included in this meta-analysis. The overall RR was 0.43 (95% CI, 0.25-0.76; 8 RCTs; Phet- erogeneity= 0.04) and 0.33 (95% CI, 0.23-0.47; 6 RCTs; Pheterogeneity = 0.93) indicated by newborn HBsAg or HBV DNA. The RR was 0.33 (95% CI, 0.21-0.50; 6 RCTs; Pheterogeneity = 0.46) and 0.32 (95% CI, 0.20-0.50; 4 RCTs; Pheterogeneity = 0.33) indicated by serum HBsAg or HBV DNA of infants 6-12 mo after birth. The RR (lamivudine vs hepatitis B immunoglobulin) was 0.27 (95% CI, 0.16-0.46; 5 RCTs; Pheterogeneity = 0.94) and 0.24 (95% CI, 0.07-0.79; 3 RCTs; Pheterogeneity = 0.60) indicated by newborn HBsAg or HBV DNA, respectively. In the mothers with viral load 〈 106 copies/mL after lamivudine treatment, the efficacy (RR, 95% CI) was 0.33, 0.21-0.53 (5 RCTs; Pheterogeneity = 0.82) for the interruption of MTCT, however, this value was not significant if maternal viral load was 〉 106 copies/mL after lamivudine treatment (P = 0.45, 2 RCTs), as indicated by newborn serum HBsAg. The RR (lamivudine initiated from 28 wk of gestation vs control) was 0.34 (95% CI, 0.22-0.52; 7 RCTs; Pheterogeneity = 0.92) and 0.33 (95% CI, 0.22-0.50; 5 RCTs; Pheterogeneity = 0.86) indicated by newborn HBsAg or HBV DNA. The incidence of adverse effects of lamivudine was not higher in the mothers than in controls (P = 0.97). Only one study reported side effects of lamivudine in newborns. CONCLUSION: Lamivudine treatment in HBV carrier- mothers from 28 wk of gestation may interrupt MTCT of HBV efficiently. Lamivudine is safe and more efficient than hepatitis B immunoglobulin in interrupting MTCT. HBV MTCT might be interrupted efficiently if maternal viral load is reduced to 〈 106 copies/mL by lamivudine treatment.
基金Supported by a Research Grant (No. 8011013315) from the Hospital Authority,Hong Kong SAR
文摘OBJECTIVES: To explore the distribution of TCM patterns in ketamine users and the inter-rater reli- ability of TCM diagnosis among TCM practitioners. METHODS: Eighty-four subjects recruited from sub- stance abuse clinics and non-governmental coun- seling services catering for ketamine abusers were examined by one or two TCM practitioners. The dis- tribution and inter-rater reliability of the TCM diag- noses between the two TCM practitioners were de- scribed and measured. RESULTS: Seven TCM patterns were differentiated. The four most common patterns were the Heart Yin deficiency (29.8%), Kidney Yang deficiency (26.2%), Kidney Yin deficiency (19.0%), and Spleen Yang defi-ciency (14.3%). The agreement between the two TCM practitioners was 59%, the kappa for the three most common patterns was 0.472 (P=O.O03). The proportion of men was lower in the Kidney Yin defi- ciency group (18.8%), in comparison to the Heart Yin deficiency (60.0%, P=0.009) and Kidney Yang de- ficiency group (59.1%, P=0.013). CONCLUSION: The differences between the TCM groups in terms of the source of referral and num- ber of drug uses other than ketamine were of bor- derline significance. Further research should focus on validating diagnostic tools and improving in- ter-rater reliability in TCM to enhance the quality of clinical trials of TCM treatments for ketamine abuse.